Navigation Links
Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Date:3/11/2013

TOKYO and SAN DIEGO, March 12, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. Astellas has exercised its right to terminate the worldwide license agreement signed in 2009, and over the months ahead the companies will work together to transfer current development activities to Ambit. Upon the effective date of termination, Ambit will regain all rights granted to Astellas and continue with the quizartinib clinical trial program.

"While our decision is based on strategic reasons, we are proud of our collaborative work with Ambit, and we are committed to working with Ambit on a smooth transition," said Yoshihiko Hatanaka , President and CEO of Astellas. "We remain committed to the field of Oncology as a major area of focus for the company and will continue to pursue our goal of becoming a Global Category Leader in Oncology." 

Michael Martino , President and CEO of Ambit, said, "With the Phase 2 study results for quizartinib that were presented at the ASH Annual Meeting last December, we and members of the medical community continue to be excited about quizartinib and its potential to meet a significant, unmet need in acute myeloid leukemia (AML) patients. We are fully committed to moving forward with the Phase 3 clinical trial plan and look forward to advancing this important drug candidate toward approval."

About QuizartinibQuizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients with relapsed or refractory AML, and in two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.

About AstellasAstellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology; Immunology including Transplantation and Infectious Diseases; Oncology; Neuroscience; and DM Complications and Kidney Diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.

About Ambit BiosciencesAmbit is a privately held biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program. Contacts:Ambit Contact:Astellas Contact:David SchullCorporate CommunicationsRusso PartnersTEL: +81-3-3244-3201, FAX: +81-3-5201-7473TEL: 212-845-427http://www.astellas.com/en david.schull@russopartnersllc.com   


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
2. Astellas to Drive PGA TOURs New Womens Initiative
3. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
7. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
8. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
9. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 In this age ... to be hopeful.  A special kind of sunglasses, from ... anxious life. Photo - http://photos.prnewswire.com/prnh/20161205/445444 ... Robert Buck, the psychotherapist who developed and patented the ... to overcoming anxiety and worry.  "Anxiety doesn,t have ...
(Date:12/5/2016)... , Dec. 5 2016 United ... Summary GlobalData,s new report, "United Kingdom ... key market data on the United Kingdom Ophthalmic ... millions of US dollars, volume (in units) and ... Coherence Tomography (OCT), Retinal Ultrasound Imaging Systems, Corneal ...
(Date:12/5/2016)...   Mallinckrodt Pharmaceuticals (NYSE: MNK ... that it received a perfect score of 100 percent ... benchmarking survey and report on corporate policies and practices ... equality, administered by the Human Rights Campaign (HRC) Foundation. ... which also earned top marks this year. ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has ... the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , Mobility Scooters give freedom to people who need help getting around. For some, ... facing a long period of rehabilitation after an illness or accident. There is a ...
(Date:12/5/2016)... ... 05, 2016 , ... "FCPX Overlay Glare is a tool that utilizes light ... rendering or complicated compositing," said Christina Austin - CEO of Pixel Film Studios. ... of lights that simulates the look of a glare. Just drag and drop ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Information Security Executive® (ISE®) Central Awards. , Awards include the Information Security ...
(Date:12/5/2016)... Isles Beach, Fla (PRWEB) , ... December 05, ... ... E. Herman as Keynote speaker for the 21st Annual International Congress on Hematologic ... making the announcement, PER® president, Phil Talamo said, “We are honored to have ...
Breaking Medicine News(10 mins):